Mourad Amrane
About
In The Last Decade
Mourad Amrane
46 papers receiving 868 citations
Peers
Comparison fields: 5 of 82
- Public Health, Environmental and Occupational Health 730
- Ophthalmology 347
- Radiology, Nuclear Medicine and Imaging 339
- Pharmaceutical Science 258
- Immunology and Allergy 172
Countries citing papers authored by Mourad Amrane
This map shows the geographic impact of Mourad Amrane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mourad Amrane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mourad Amrane more than expected).
Fields of papers citing papers by Mourad Amrane
This network shows the impact of papers produced by Mourad Amrane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mourad Amrane. The network helps show where Mourad Amrane may publish in the future.
Co-authorship network of co-authors of Mourad Amrane
This figure shows the co-authorship network connecting the top 25 collaborators of Mourad Amrane. A scholar is included among the top collaborators of Mourad Amrane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mourad Amrane. Mourad Amrane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 0 | |
| 3 | 4 | |
| 4 | 7 | |
| 5 | 2 | |
| 6 | 28 | |
| 7 | Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials | 1 |
| 8 | 27 | |
| 9 | Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study | 1 |
| 10 | 100 | |
| 11 | Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED) | 1 |
| 12 | Patients with Moderate to Severe Dry Eye Disease in Routine Clinical Practice in the UK - Physician and Patient’s Assessments | 3 |
| 13 | 40 | |
| 14 | 10 | |
| 15 | The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion | 1 |
| 16 | Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial | 10 |
| 17 | 1 | |
| 18 | 4 | |
| 19 | 17 | |
| 20 | [Complicated jejunal diverticula. Apropos of 4 recent cases]. | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.